Mondobiotech Holding AG Company presentation

Scientific Snapshot Information: DK-1001-01
§� IPF is a chronic, progressive form of lung disease characterized
by fibrosis of the supporting framework (interstitium) of the
lungs. By definition, the term is used only when the cause of the
pulmonary fibrosis is unknown ("idiopathic").
IPF Lung
Inhaled DK-1001
§� Mechanism of Action:
Pleiotropic cytokine produced by lymphocytes. Key effects are
anti-fibrotic, anti-proliferative, anti-viral, anti-tumor and
immunomodulatory properties (promotes Th1 differentiation,
NK cell activity and antigen presentation by macrophages).
DK-1001 is a recombinantly-produced (E. coli) 140 amino acid
polypeptide. It acts via activating specific membrane receptors,
which are present on B-cells, T-cells, macrophages, endothelial
cells, epithelial cells, alveolar cells, fibroblasts, and smooth
muscle cells.
Signaling leads to the recruitment of Janus kinases, which bind
to the intracellular domain of the receptor, leading to its
tyrosine phosphorylation and subsequent association with the
signal transducer and activator of transcription (STAT) protein.
Phosphorylated STAT is then translocated to the nucleus,
where it activates the transcription of respective target genes.
§� Key data (in vivo human PoC data):
3 x weekly s.c. administration of DK-1001 (200µg) over 9
month period results in an improvement of pulmonary
function (∆ Total Lung Capacity)
Liters
months
46